2篇
您的检索式：作者名="Xianping Shi"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intermetallic Compounds in the Banded Structure and Their Effect on Mechanical Properties of Al/Mg Dissimilar Friction Stir Welding Joints显示文摘Dissimilar friction stir welding(FSW) between aluminum and magnesium alloy was performed, using various tool rotational speed(TRS) at a ?xed travel speed, with tool offset to aluminum to investigate the formation of intermetallic compounds(IMCs) in the banded structure(BS) zone and their effect on mechanical properties. Large quantities of IMCs, in the form of alternating bands of particles or lamellae, were found in the BS zone, where drastic material intermixing occurred during FSW. The BS microstructural characters in terms of the morphology of the bands and the quantity and distribution of IMC particles varied with TRS. All welds exhibited brittle fracture mode with their fracture paths propagating mainly in/along the IMCs in the BS. It is shown that these BS microstructural characters have signi?cant effect on the mechanical properties of the joints. Suggestions on tailoring the BS microstructure were proposed for improving the strength of the BS zone and the ?nal mechanical properties of the Al/Mg FSW joints. | Hui Shi Ke Chen Zhiyuan Liang Fengbo Dong Taiwu Yu Xianping Dong Lanting Zhang Aidang Shan | 2017 | Journal of Materials Science & Technology2017，33，4： | 8 |
| 2 | Stabilization of MYC G-quadruplex DNA by ruthenium(II)complex overcomes imatinib resistance in chronic myeloid leukemia cells harboring T315I mutation显示文摘The key pathogenesis of chronic myeloid leukemia(CML)is the formation of BCR-ABL fusion gene,encoding a 210 kDa Bcr-Abl tyrosine kinase,which is crucial for the occurrence and development of CML.Imatinib(IM)is the first targeted anticancer drug approved by FDA for the treatment of CML;however,some patients,especially those in accelerated phase and blastic phase,develop primary or secondary drug resistance to IM.Particularly,the most challenging resistance is caused by T315I mutation of Bcr-Abl,which represents approximately 15%–20%of all acquired mutations and renders cell resistant to a variety of tyrosine kinase inhibitors.1,2 Thus,there is an urgent need to develop novel strategies to overcome Bcr-Abl T315I-meidated IM resistance. | Yuening Sun Xin Chen Siyan Liao Aochu Liu Huan Zhou Liling Jiang Wa Ding Wenjie Mei Jinbao Liu Xianping Shi | 2023 | Genes & Diseases2023，10，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员